Overview
Acromegaly is a rare but important endocrine disorder caused by long-term excess secretion of growth hormone (GH), usually from a pituitary somatotroph adenoma, leading to elevated insulin-like growth factor 1 (IGF-I). The disease develops slowly, so its signs are often subtle at first and diagnosis is frequently delayed for 6 to 10 years. During that time, patients may experience progressive changes in appearance, joint pain, sleep problems, metabolic abnormalities, and reduced quality of life.
Early recognition matters because acromegaly is associated with higher risks of hypertension, diabetes, sleep apnea, cardiomyopathy, osteoarthritis, and increased mortality if left untreated. The good news is that more accurate hormone testing, improved imaging, and emerging artificial intelligence tools are making earlier diagnosis more realistic than before.
Why acromegaly is often missed
The classic features of acromegaly are enlargement of the hands and feet, widening of facial features, a protruding jaw, and spacing of the teeth. These changes are diagnostically helpful, but many patients do not present with obvious acral enlargement early in the disease. Instead, they may first report nonspecific complaints such as fatigue, headaches, snoring, carpal tunnel syndrome, sweating, joint pain, menstrual irregularities, erectile dysfunction, or worsening glucose intolerance.
Because these symptoms are common in many other conditions, acromegaly may not be considered right away. This is one reason the diagnosis is often delayed for years. Clinicians are encouraged to think about acromegaly when several compatible features occur together, especially when symptoms cluster in a pattern that is unusual for the patient’s age.
Who should be screened
Routine population screening for acromegaly is not recommended because the disease is rare. Instead, testing should be targeted to patients with suggestive clinical features. Screening is particularly appropriate in people with any of the following:
– Enlargement of hands, feet, or ring/shoe size
– Coarsening of the face or jaw protrusion
– Unexplained sleep apnea
– Carpal tunnel syndrome, especially if bilateral or recurrent
– Arthralgia or degenerative joint disease out of proportion to age
– Excessive sweating or oily skin
– Unexplained hypertension, diabetes, or impaired glucose tolerance
– Pituitary incidentaloma or a known pituitary mass
– Combination of several related comorbidities without another clear explanation
New approaches using comorbidity clustering, electronic medical records, and artificial intelligence may help identify patients earlier by detecting patterns that would otherwise be overlooked.
Initial biochemical testing
The preferred first-line screening test for acromegaly is serum IGF-I. IGF-I is more stable than GH because it reflects integrated GH secretion over time rather than a single random measurement. In untreated acromegaly, IGF-I is typically elevated above the age-adjusted reference range.
Interpretation of IGF-I must be careful and context-dependent. Results should be assessed using assay-specific, age-adjusted reference ranges, and when possible, sex-specific considerations. Different laboratories may use different methods, so values should not be compared blindly across institutions.
Several conditions can alter IGF-I and complicate interpretation, including:
– Diabetes mellitus, especially if poorly controlled
– Liver disease
– Renal disease
– Obesity
– Pregnancy
– Oral estrogen use, which can lower IGF-I
– Severe systemic illness or malnutrition
A normal IGF-I level makes active acromegaly less likely, but it does not always fully exclude the diagnosis if clinical suspicion remains high, particularly in early disease or when assay issues are suspected.
When biochemical and clinical findings do not match
Sometimes the clinical picture suggests acromegaly, but the IGF-I level is borderline or normal. In such cases, the recommended approach is to repeat IGF-I using the same or a well-validated assay and then assess GH suppression with an oral glucose tolerance test (OGTT).
This is especially important because GH secretion is pulsatile and random GH levels can vary widely. A single random GH value is therefore not reliable enough to confirm or exclude acromegaly on its own.
Oral glucose tolerance test and GH suppression
The OGTT remains the gold-standard confirmatory test for acromegaly. In healthy individuals, glucose suppresses GH secretion. In acromegaly, GH fails to suppress normally.
During the test, serum GH is measured after a glucose load, and the nadir GH is interpreted using assay-specific cutoffs. With modern ultrasensitive GH assays, the recommended nadir threshold has been lowered to approximately 0.4 µg/L in many settings, though the exact cutoff depends on the assay and the laboratory standardization used.
It is important to interpret OGTT results in the context of the assay, because older methods and newer ultrasensitive assays are not directly interchangeable. Borderline results may require repeat testing or specialist review.
Role of random GH measurements
Random GH levels are often elevated in acromegaly and may correlate with tumor burden, but they are not the preferred diagnostic test because GH is secreted in bursts. A high random GH may support suspicion, especially if markedly elevated, but diagnosis should rely on IGF-I and GH suppression testing rather than random sampling alone.
Imaging after biochemical confirmation
Once biochemical testing confirms acromegaly, pituitary magnetic resonance imaging is used to identify the source, most commonly a pituitary adenoma. High-resolution MRI can detect very small lesions and help define tumor size, extension into nearby structures, and proximity to the optic chiasm.
In selected cases where MRI is inconclusive or equivocal, advanced imaging techniques such as PET/MRI may provide additional information. These methods can be useful in difficult diagnostic situations, recurrent disease, or cases where tumor localization is uncertain.
Emerging technologies in diagnosis
Recent advances are expanding the diagnostic toolkit for acromegaly. Artificial intelligence may analyze facial photographs, dental images, and electronic medical record data to flag patients at risk before a formal diagnosis is made. Radiomics, which extracts quantitative features from imaging studies, may also help characterize pituitary tumors and improve detection.
AI-assisted facial recognition is especially promising because facial coarsening can be subtle and easy to miss in routine practice. Similarly, automated analysis of longitudinal health data may reveal repeated patterns such as sleep apnea, carpal tunnel syndrome, and glucose abnormalities that together suggest acromegaly.
These approaches are not yet replacements for hormonal testing, but they may become valuable screening aids, particularly in primary care, sleep medicine, orthopedics, and endocrinology settings.
Comorbidities that should raise suspicion
Acromegaly affects many organs and systems. Common associated conditions include:
– Obstructive sleep apnea
– Hypertension
– Type 2 diabetes mellitus
– Arthropathy and back pain
– Carpal tunnel syndrome
– Cardiomyopathy and arrhythmias
– Colon polyps in some patients
– Reproductive dysfunction
The presence of multiple comorbidities, especially when they develop together or progress unexpectedly, should prompt consideration of acromegaly. In practice, the disease is often recognized not because of one striking symptom, but because of a constellation of problems that seem disproportionate for the patient’s age.
Practical diagnostic approach
A stepwise approach is recommended:
1. Suspect acromegaly based on characteristic features or comorbidity clusters.
2. Measure serum IGF-I using a validated age-adjusted assay.
3. If IGF-I is elevated, proceed to confirmatory GH suppression testing with OGTT.
4. If results are discordant, repeat IGF-I and consider specialist interpretation.
5. Once biochemically confirmed, obtain pituitary MRI to localize the tumor.
This sequence helps avoid both underdiagnosis and unnecessary testing.
Differential diagnosis and interpretation pitfalls
Several issues can lead to false reassurance or misdiagnosis. A borderline IGF-I may reflect assay variation, patient age, or another medical condition rather than true absence of disease. Conversely, mildly abnormal results may occur in non-acromegalic states. Obesity, poorly controlled diabetes, malnutrition, liver failure, renal failure, and estrogen exposure are particularly important confounders.
Because of these pitfalls, expert endocrine review is valuable when the laboratory picture does not clearly match the clinical picture. Repeating testing, verifying assay type, and reviewing concurrent illnesses can prevent delay.
Why earlier diagnosis changes outcomes
Earlier diagnosis allows earlier treatment, which may include pituitary surgery, medical therapy such as somatostatin receptor ligands, GH receptor antagonists, or dopamine agonists in selected cases, and occasionally radiotherapy. While treatment is beyond the scope of diagnosis alone, recognizing the disease sooner makes cure or control more likely and reduces the burden of irreversible complications.
Patients diagnosed earlier may have a lower risk of long-term cardiovascular, metabolic, and musculoskeletal damage. They may also experience meaningful improvements in symptoms such as sweating, fatigue, and sleep quality once hormone excess is controlled.
Take-home message
Acromegaly is a slowly evolving disorder that is often overlooked because its early symptoms are nonspecific. Serum IGF-I is the best initial screening test, and GH suppression during OGTT is the key confirmatory study when needed. Careful interpretation is essential because multiple medical conditions can affect hormone levels. With improved laboratory methods, high-resolution imaging, and new AI-based screening tools, there is real potential to diagnose acromegaly earlier and improve patient outcomes.